XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Restatement of Previously Issued Financial Statements (Tables)
9 Months Ended
Sep. 30, 2023
Restatement of Previously Issued Financial Statements  
Summary of effect of the restatement on each financial statement line item

Condensed Consolidated Balance Sheet as of September 30, 2023 (Successor) (Unaudited)

As Reported

Adjustment

Reference

As Restated

Contingent consideration liability

 

$

74,505

$

6,656

(a)

$

81,161

Total liabilities

 

 

139,359

 

6,656

 

146,015

Additional paid-in capital

 

 

362,114

 

17,555

(a) (d) (e) (f)

 

379,669

Accumulated deficit

 

 

(423,148)

 

(24,211)

(a) (b) (c) (d) (e) (f)

 

(447,359)

Total AEON Biopharma, Inc. stockholders’ deficit

 

 

(121,740)

 

(6,656)

 

(128,396)

Total stockholders' deficit

 

 

(121,740)

 

(6,656)

 

(128,396)

Condensed Consolidated Statement of Operations and Comprehensive loss for the period from July 22, 2023 to September 30, 2023 (Successor) (Unaudited)

As Reported

Adjustment

Reference

As Restated

Selling, general and administrative

 

$

5,460

$

(195)

(d)

$

5,265

Research and development

 

 

6,383

 

5

(d)

 

6,388

Change in fair value of contingent consideration

 

 

(69,715)

 

(6,224)

(a)

 

(75,939)

Total operating costs and expenses

 

 

(57,872)

 

(6,414)

 

(64,286)

(Loss) income from operations

 

 

57,872

 

6,414

 

64,286

(Loss) income before taxes

 

 

43,875

 

6,414

 

50,289

(Loss) income and comprehensive (loss) income

 

 

43,875

 

6,414

 

50,289

Basic and diluted net (loss) income per share

 

$

1.19

$

0.16

$

1.35

Condensed Consolidated Statement of Operations and Comprehensive loss for the period from July 1, 2023 to July 21, 2023 (Predecessor) (Unaudited)

As Reported

Adjustment

Reference

As Restated

Change in fair value of convertible notes

 

$

2,582

$

(15,831)

(c)

$

(13,249)

Change in fair value of embedded forward purchase agreements and derivative liabilities

 

 

(4,959)

 

(6,830)

(b)

 

(11,789)

Total other (loss) income, net

 

 

(2,372)

 

(22,661)

 

(25,033)

(Loss) income before taxes

 

 

(5,000)

 

(22,661)

 

(27,661)

(Loss) income and comprehensive (loss) income

 

 

(5,000)

 

(22,661)

 

(27,661)

Basic and diluted net (loss) income per share

 

$

(0.04)

$

(0.16)

$

(0.20)

Condensed Consolidated Statement of Operations and Comprehensive loss for the period from January 1, 2023 to July 21, 2023 (Predecessor) (Unaudited)

As Reported

Adjustment

Reference

As Restated

Change in fair value of convertible notes

 

$

(3,528)

$

(15,831)

(c)

$

(19,359)

Change in fair value of embedded forward purchase agreements and derivative liabilities

 

 

(4,959)

 

(6,830)

(b)

 

(11,789)

Total other (loss) income, net

 

 

(8,373)

 

(22,661)

 

(31,034)

(Loss) income before taxes

 

 

(38,017)

 

(22,661)

 

(60,678)

(Loss) income and comprehensive (loss) income

 

 

(38,017)

 

(22,661)

 

(60,678)

Basic and diluted net (loss) income per share

 

$

(0.28)

$

(0.16)

$

(0.44)

Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from July 1, 2023 to July 21, 2023 (Predecessor) (Unaudited)

As Reported

Adjustment

Reference

As Restated

Net loss

 

$

(5,000)

$

(22,661)

(b) (c)

$

(27,661)

Balance as of July 21, 2023 (Predecessor)

 

 

(288,159)

 

(22,661)

 

(310,820)

Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from January 1, 2023 to July 21, 2023 (Predecessor) (Unaudited)

As Reported

Adjustment

Reference

As Restated

Net loss

 

$

(38,017)

$

(22,661)

(b) (c)

$

(60,678)

Balance as of July 21, 2023 (Predecessor)

 

 

(288,159)

 

(22,661)

 

(310,820)

Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from July 22, 2023 to September 30, 2023 (Successor) (Unaudited)

As Reported

Adjustment

Reference

As Restated

Balance as of July 22, 2023 (Successor)

 

$

(167,976)

$

(12,880)

$

(180,856)

Net income

 

 

43,875

 

6,414

(a) (d)

 

50,289

Stock-based compensation expense

 

 

2,361

 

(190)

(d)

 

2,171

Balance as of September 30, 2023 (Successor)

 

 

(121,740)

 

(6,656)

 

(128,396)